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Through modifications in the fine membrane structure, cell–cell or cell–matrix interactions, and/or modulation of intracellular signaling
pathways, sphingolipids can affect the tumorigenic potential of numerous cell types. Whereas ceramide and its metabolites have been described as
regulators of cell growth and apoptosis, these lipids as well as other sphingolipid molecules can modulate the ability of malignant cells to grow
and resist anticancer treatments, and their susceptibility to non-apoptotic cell deaths. This review summarizes our current knowledge on the
properties of sphingolipids in the regulation of cancer cell death and tumor development. It also provides an update on the potential perspectives of
manipulating sphingolipid metabolism and using sphingolipid analogues in anticancer therapy.
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During the last few years, a growing body of evidence has
accumulated indicating that cancer cells can die by several
ways as defined by distinct morphological and biochemical
features [1,2]. Depending on the cell type and the death
stimulus, multiple mechanisms leading to apoptosis, necrosis
or intermediate cell deaths exhibiting some characteristics of
apoptosis, necrosis or both have been described. Different names
and definitions were given including apoptosis-like and necrosis-
like cell deaths, paraptosis, apoptonecrosis, caspase-dependent
and -independent cell death, mitotic catastrophe as well as
autophagic cell death [3]. However, since all these different types
of cell death are not fully characterized at the morphological and
biochemical levels, no precise or unequivocal definition can be
delineated for all of them.
In a recent review, the nomenclature committee on cell death
proposed some recommendations to unify criteria for the defi-
nition of the different types of cell death [4]. Apoptosis is
mostly characterized by reduction of the cellular volume, chro-
matin condensation and nuclear fragmentation. In most (but not
all) cases, apoptosis is associated with caspase activation and
DNA fragmentation. Autophagic cell death (or preferably cell
death associated with autophagy) occurs without chromatin
condensation and is morphologically defined by the presence in
the cytoplasm of two-membraned vacuoles containing degen-
erating organelles. Mitotic catastrophe is a form of cell death
that occurs during the metaphase leading to aneuploidy and
multinucleation and is most likely a consequence of abortive
mitosis and/or cytokinesis. Necrosis is associated with plasma
membrane disruption, swelling of organelles, oncosis and mo-
derate chromatin condensation.
The molecular pathways leading to autophagic cell death,
mitotic catastrophe and necrosis are largely unknown. Whereas
recent data point to the putative involvement of cytotoxic
sphingolipids (SLs) such as ceramide or its immediate me-
tabolic derivatives not only in the induction of apoptosis but
also in autophagic cell death and necrosis, some other SLs such
as psychosine, a catabolite of galactosylceramide, were shown
to trigger mitotic catastrophe (see below).
One of the characteristics of cancer cells is to resist cell death
owing to the development of different resistance mechanisms
including up-regulation of the expression of anti-apoptotic genes,
inactivation of pro-apoptotic genes as well as immunosuppres-
sive strategies to escape from cellular killers [5]. With regard toanti-apoptotic proteins, the expression of some Bcl-2 (B cell
lymphoma 2) family members, including Bcl-2 and viral homo-
logues, is frequently up-regulated in cancer cells. Those proteins
confer resistance to chemotherapy, radiotherapy, as well as ce-
ramide and its metabolites [6–8]. The anti-apoptotic mecha-
nism relies mainly on the capacity of anti-apoptotic Bcl-2 family
members to stabilize mitochondrial and endoplasmic reticulum
membranes, blocking the re-localization of pro-apoptotic mito-
chondrial proteins (such as cytochrome c) [9] and calcium into
the cytosol [10]. Other proteins such as FLIP (FADD-like inter-
leukin-1 β-converting enzyme Inhibitory Protein) and IAPs (In-
hibitor of Apoptosis Proteins), which are overexpressed in some
cancer cells, interfere with caspase activation [5]. Treatment by
siRNA for X-IAP overcomes the resistance of glioma cells in
response to ceramide [11] indicating that IAP proteins can inhibit
ceramide-induced cell death.
Concerning the pro-apoptotic genes, different mutations
leading to the loss of protein expression or function have been
reported in cancer cells. For instance, p53, BAX and APAF1
(Apoptotic Protease Activating Factor 1) mutations were re-
ported in various cancer cells. Moreover, death receptors such
as CD95 and TRAIL-R (Tumor Necrosis Factor-Related
Apoptosis Inducing Ligand receptor) are frequently down-
regulated or mutated in many solid tumors, myelomas and
leukemia. These phenomena are part of the mechanisms
developed by malignant cells to resist chemo- and radiotherapy
and to escape from the immune system [5]. In some instances,
ceramide analogues can overcome cell death resistance by
activating caspase-dependent and -independent cell death (see
below).
2. Sphingolipids as regulators of cancer cell death
The effects of SLs on the regulation of cell growth are
remarkably complex. This complexity is exemplified by the
influence that SLs exert on malignant transformation and tumor
progression. Whereas some SLs tend to promote tumorigenesis,
some others repress tumor extension, making these lipids viewed
as double-edged swords with regard to their action on cancer
cells (Fig. 1).
2.1. Sphingolipids as tumorigenic molecules
Accumulating evidence indicates that some SLs can fa-
cilitate tumor growth, for instance by inhibition of tumor cell
Fig. 1. Sphingolipids as positive or negative modulators of the susceptibility of
malignant cells to cell death. Abbreviations: CD, cell death; Cer, ceramide; Cer-
1P, ceramide 1-phosphate; GalCer, galactosylceramide; GalSph, galactosyl-
sphingosine (psychosine); GD3, ganglioside GD3; GlcCer; glucosylceramide;
GM3, ganglioside GM3; LacCer, lactosylceramide; MDR, multidrug resistance;
Sph, sphingosine; Sph-1P, sphingosine 1-phosphate.
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abilities and tumoral angiogenesis, or by participating to tumor
cell escape from the immune system. Among those SLs, sialic
acid-bearing glycosphingolipids, i.e., gangliosides, and sphin-
gosine 1-phosphate (S1P) are presently considered to play a
major role in tumor biology.
2.1.1. Tumorigenic effect of gangliosides
The role of gangliosides in tumor development is complex,
as these lipids can greatly influence cell death, invasion and
metastasis [12,13]. One of the characteristics of tumor cells is an
enhanced expression of various gangliosides. For instance, GD3
expression is markedly increased in melanoma cells as com-
pared to human melanocytes. In addition, highly metastatic cells
expressed more GD3 than poorly metastatic cells (see [12] and
references therein). Consequently, this ganglioside has been
proposed as a target for immunotherapy of cancer. For ins-
tance, anti-GD3 monoclonal antibodies can inhibit human me-
lanoma cell growth in vitro and in vivo [14]. Recently, a chimeric
anti-GD3 antibody (KM871) has been tested in phase I clinical
trials in patients with metastatic melanoma [15], and another was
evaluated in a phase III clinical trial against small cell lung
cancers [16]. Furthermore, epigenetic modifications of gangli-
oside expression (using antisense vectors against GD3-synthase
or glucosylceramide synthase) have demonstrated an inhibition
of tumor incidence and metastatic potential of neuroblastoma
[17,18] or melanoma [19]. Another putative pro-tumoral gangli-
oside is GM3. Indeed, the metastatic and invasive potential of
mouse melanoma B16 seems to be correlated with the level of
GM3 expression at the cell surface [20]. The presence of sub-
stantial amounts of GM3 on humanmelanomas and other tumors
makes this glycolipid a possible target for cancer immunother-
apy [21]. Consequently, GM3 has been used to develop vaccines
and monoclonal antibody strategies. For instance, a phase I clinical
trial using anti-GM3 human monoclonal antibody (L612) was
recently performed in patients with metastatic melanoma [22].Other gangliosides, often quantitatively minor in healthy cells,
could be involved in promotion of tumor cell migration and inva-
siveness. For instance, the expression of disialyl-GaINAc-Lc4Cer
(RM2 antigen) or monosialyl-Gb5 has been associated with
metastatic properties of renal carcinoma [23] or mammary
carcinoma [24], respectively.
How can gangliosides promote tumor development? Gang-
liosides present at the tumor cell surface might regulate crosstalks
with the cellular environment (healthy tissue cells, endothelial
cells as well as immune cells), participating to the development of
tumor and its invasive/metastatic properties. The communication
between cells involves molecular interactions that have been
mainly studied as protein–protein interactions, for instance in the
immunological synapse. However, though this research area has
received less attention, glycosyl epitopes can also act in cellular
interactions, especially in cancer development modulation [25].
Thus, tumor cell gangliosides can interact with neighboring cells
by acting as adhesion molecules, functional ligands or bioactive
soluble factors. In glycosynapses, gangliosides may modulate not
only cell adhesion but also signal transduction [26]. For instance,
GM3 on B16 melanoma cell surface is strongly involved in
adhesion to endothelial cells and induces complex signaling in
these cells. Another possibility for ganglioside involvement in
cellular adhesion is the interaction of the disialo epitope of certain
gangliosides with sialic acid binding proteins named Siglecs
(Sialic acid-binding Immunoglobulin-like Lectins). Because
Siglecs are expressed on various types of blood cells, tumor
cells expressing high levels of disialogangliosides can bind to
Siglecs of blood cells, leading to the formation of cell clumps
triggering microembolisms. Consequently, activated platelets
release stimulating factors for endothelial cells, thereby inducing
expression of adhesion molecules and thus allowing tumor cell
adhesion and translocation out of the vessel to initiate metastases.
Moreover, tumor cells shed gangliosides into the microenviron-
ment, a phenomenon that can modulate angiogenesis and immu-
nosurveillance. For instance, extracellular GD3 stimulates VEGF
production whereas GM3 can inhibit EGF receptor tyrosine
kinase activity [18,27].
Gangliosides in particular, but putatively other SLs as well,
can suppress the antitumoral immune response [28]. The anti-
tumor activity mediated by the immune system uses various
mechanisms, such as cell-induced cytotoxicity. For instance,
cytotoxic T lymphocytes (CTL) and NK cells, but also macro-
phages and granulocytes, can kill tumor cells. The interaction
between killer cells and tumor cells and the regulation of killing
involve adhesion molecules, activating and inhibiting receptors,
co-stimulating molecules, death ligands and their receptors. The
regulatory role of gangliosides in these complex molecular
interactions is only partly elucidated. Thus, it has recently been
demonstrated that Siglec-7 expressed by monocytes and NK
lymphocytes induces an inhibitory effect on killer function and
has a preferential binding for α 2,8-linked disialic acids which
are displayed by gangliosides such as GD3, GD2 and GT1b
[29,30]. As a matter of fact, GD3 present on tumor target cells
can modulate NK-mediated cytotoxicity using Siglec-7 inter-
action. Further observations support the hypothesis that gang-
liosides may be indirectly active in the suppression of the anti-
Table 1
Examples of in vitro or in vivo effects of (epi)genetic manipulation of sphingolipid metabolism on the viability and tumorigenicity of cancer cells
Enzyme Cell type/origin Type of manipulation Consequence on cell viability References
Glucosyl ceramide
synthase
Human MCF-7 breast cancer Overexpression Resistance to adriamycin and ceramide [180]
Human MCF-7 breast cancer Knockdown (by antisense
constructs or ODNs)
Restoration of anticancer drug-induced
apoptosis in resistant cells
[181,197,198]
Human Jurkat T leukemia Overexpression No effect on stress-induced DNA fragmentation [146]
Murine MEB4 melanoma Knockdown (by an antisense
construct)
Reduction in tumorigenicity [19]
Murine B16 melanoma Deficient (GM95) and corrected
(GM95/GCS) cells
No difference in anticancer drug-induced
apoptosis
[147]
GD3 synthase Human HuT78 T cell lymphoma and
U937 leukemia
Overexpression Induction of apoptosis [199]
Knockdown (by antisense
ODNs)
Inhibition of Fas cross-linking-induced
apoptosis
Rat F-11 neuroblastoma Knockdown (by an antisense
construct)
Reduction in tumor growth [17]
Human HT29 colon cancer Knockdown (by an antisense
construct)
Inhibition of TNF-induced cell death [200]
GM3 synthase Murine MBT-2 bladder carcinoma Overexpression Increase in apoptosis and reduction of tumor
growth
[201]
Ganglioside
sialidase
Murine B16 melanoma Overexpression Reduction in lung metastases [202]
Human HCT-115, HCT116, DLD-1
colon cancer
Overexpression Inhibition of sodium butyrate-induced apoptosis [40]
Sphingomyelin
synthase 1
Murine WR19L lymphoma Deficient (WR/SM-) Partial resistance to anti-Fas-induced apoptosis [108]
Corrected (WR/SMS1) Increase in anti-Fas-induced apoptosis
Neutral SMase 2 Human MCF-7 breast cancer Overexpression Growth inhibition [126]
Knockdown (by siRNA) Increase in cell proliferation [128]
Acidic SMase Human EBV-transformed
lymphoid cells
Deficient (Niemann–Pick) Impairment in stress-induced apoptosis see [72]
for review
No defect in stress-induced apoptosis see [72]
for review
Acidic ceramidase Murine L929 fibrosarcoma Overexpression Inhibition of TNF-induced apoptosis [140]
Murine L929 fibrosarcoma Overexpression Inhibition of TNF-induced caspase-independent
cell death
[61]
Human EBV-transformed lymphoid
cells
Deficient (Farber) No defect in stress-induced apoptosis [203]
C18-ceramide
synthase (LASS1)
Human UM-SCC-22A squamous cell
carcinoma of hypopharynx
Overexpression Induction of apoptotic cell death [204]
Sphingosine kinase 1 Human Jurkat T leukemia Overexpression Partial inhibition of ceramide, serum starvation
and Fas-induced apoptosis
[205]
Rat PC12 pheochromocytoma Overexpression Inhibition of ceramide and serum starvation-
induced apoptosis
[206]
Human PC-3 and LNCaP prostate cancer Overexpression Inhibition of anticancer drug-induced apoptosis [139]
Knockdown (by siRNA) Induction of apoptosis
Human HL-60 leukemia Overexpression Inhibition of anticancer drug-induced apoptosis [207]
Human A-375 and Mel-2a melanoma Overexpression Inhibition of Fas- and ceramide-induced
apoptosis
[208]
Knockdown (by siRNA) Decreased resistance to apoptosis
Murine erythroleukemia Overexpression Resistance to serum starvation-induced
apoptosis
[209]
Overexpression of catalytically-
inactive form
Sensitization to serum starvation-induced
apoptosis
Human MCF-7 breast cancer Overexpression Increase in autophagy and inhibition of serum
starvation-induced apoptosis
[90]
Knockdown (by siRNA) Decrease in autophagy and stimulation of serum
starvation-induced apoptosis
Sphingosine kinase 2 Rat PC12 pheochromocytoma Overexpression Stimulation of serum starvation-induced apoptosis [210]
Murine NIH3T3 fibroblasts Overexpression Inhibition of DNA synthesis [211]
Murine NIH3T3 fibroblasts Overexpression Stimulation of anticancer drug and serum
starvation-induced apoptosis
[134]
S1P phosphatase 1 Murine NIH3T3 fibroblasts Overexpression Increase in stress induced-apoptosis [212]
Human HEK293 embryonic kidney Overexpression Induction of apoptosis upon addition of S1P [135]
S1P lyase Human HEK293 embryonic kidney Overexpression Increase in serum starvation-induced apoptosis [136]
Human A549 lung cancer Overexpression Increased sensitivity to cisplatin, carboplatin,
doxorubicin
[213]
Abbreviation: ODNs, oligodeoxynucleotides.
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Table 2
Examples of in vitro or in vivo effects of sphingolipid analogues on cell death and tumorigenicity of cancer cells (short-chain ceramides and FTY720 are not presented
in this table; the reader is referred to the text)
SL analogue Cell type In vitro effect In vivo effect Reference
B13 Human SW403 and Lovo colon
cancer cells
Apoptosis Prevention of
liver metastases
[159]
B13 and D-e-MAPP Human melanoma cells Reduction in cell
proliferation and apoptosis
[214]
B13 (R and S) Human prostate LNCaP and PC3
cancer cells
Apoptosis Reduction of tumor
volume after irradiation
[158]
Adamantyl-ceramide Human MCF-7/Adr breast
cancer cells
Cell death (IC50 ∼ 25 μM) [156]
Thiouracil-ceramide Human CEM leukemia cells Caspase- independent
cell death (IC50 ∼ 1.7 μM)
Reduction of tumor
(human colon cancer)
mass
[215]
S18 Murine and human
neuroblastoma cells
Apoptosis Prevention of teratoma
formation
[216–218]
PEITC-Sa Human HL-60 leukemia cells Apoptosis [161]
RZ-2 Human HL-60 leukemia cells Apoptosis (IC50 ∼ 6 μM) [219]
4,6-diene-ceramide Human MCF-7 breast cancer cells Apoptosis (IC50 ∼ 11 μM) [157]
C6-pyridinium
ceramide bromide
Human HepG2 hepatoma,
MCF-7 breast cancer, and
head and neck squamous cell
carcinoma
Reduction in cell survival
(IC50 ∼ 0.25–8 μM)
[220,221]
AD2646, AD2687 Human Jurkat and HL-60
leukemia cells
Caspase-dependent
and caspase-independent
cell death (IC50 ∼ 1 μM)
[66,222]
AD2765 Human M059J glioma
cells
Cell death
(IC50 > 10 μM)
[223]
Chemical names of SL analogues: B13 (R): (1R,2R)-2-(N-myristoylamino)-1-(4′-nitrophenyl)-1,3-propanediol; D-e-MAPP: (1S,2R)-2-N-myristoylamino-1-phenyl-1-
propanol; Adamantyl-ceramide: (2S,3R)-2-(N-adamantoyl)-(4E)-octadecen-1, 3-diol; S18: N-oleoyl-(2-amino-1,3-propanediol); PEITC-Sa: phenethylisothiocyanate-
substituted sphinganine; RZ-2: (2R,3Z)-2-acetylamino-3-octadecen-1-ol; 4,6-diene-ceramide: (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-diol; AD2646:
(2R,3R)-2-(N-tetradecylamino)-1-(4-nitrophenyl)-1,3-propanediol; AD2687: (2R,3R)-2-(N,N,N-trimethylamino)-1-(N-tetradecanoyl-4-aminophenyl)-1,3-propanediol.
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For instance, exogenous and tumor-derived gangliosides can
inhibit antigen presentation by monocytes, down-regulate MHC
molecule expression by dendritic cells [31] and suppress the
function of monocyte-derived dendritic cells [32]. Exogenous
gangliosides can inhibit B and T cell activation and helper T cell
functions [33]. Released tumor gangliosides can also bind to IL-
2 and, consequently, inhibit the interaction of the cytokine with
its receptor [34]. In addition, exogenous GM3 induces inhibition
of CD4 molecule expression that could prevent T lymphocyte
activation [35]. Finally, some exogenous gangliosides could
reduce Th1 immune response and favor Th2 response. The
mechanisms involved in these effects remain poorly understood,
but may include inhibition of IFNγ production; enhancement of
IL-4 dependent differentiation of Th2 cells, known to inhibit Th1
responses; alteration of Th1 cell differentiation through an
impairment of dendritic cell development and antigen presen-
tation; and a higher susceptibility of Th1 cells to ganglioside-
induced apoptosis [28,36–38]. Thus, gangliosides participate to
the suppression of Th1 response, considered to be essential for
the immune defense against tumor cells.
2.1.2. Tumorigenic effect of sphingosine 1-phosphate
By regulating cell death signaling, SLs can largely contribute
to tumor promotion. Some SL metabolites, such as sphingosine
1-phosphate (S1P), ceramide 1-phosphate and lactosylceramide
negatively modulate cell death and/or promote cell prolifera-tion. For instance, ceramide 1-phosphate stimulates cell survival
and blocks apoptosis (see review by [39]). Recently, lactosyl-
ceramide, produced by the Neu3 sialidase, has also been pro-
posed to inhibit apoptosis of colon cancer cells, mainly through
an increased Bcl-2 expression and diminished caspase activation
[40]. Expression of this ganglioside sialidase has been reported
to be greatly enhanced in different aggressive tumors. It is likely
that tumor cells use such anti-apoptotic mechanisms involving
SLs to escape death induced by tumor immunosurveillance.
Among the anti-apoptotic SLs, S1P is clearly considered as a
tumor promoter, favoring cellular transformation, tumor pro-
liferation and cell survival (see articles by Obeid et al. [224] and
Spiegel et al. [225] in this issue). Inside the tumor cell, S1P
interferes with cell death signaling pathways, inhibiting cell
death and favoring cell growth and cell movement. One of the
putative anti-apoptotic mechanisms of S1P is to prevent
ceramide-induced mitochondrial events such as cytochrome c
release and caspase activation [41,42]. In addition to these direct
effects on tumor cells, S1P alters several mechanisms that
trigger cell survival and growth. Thus, S1P promotes tumor
angiogenesis, a process vital for the development of aggressive
tumors (for reviews, see [43,44]). For instance, S1P can act on
cancer development by: (i) facilitation of tumor cell activation
by VEGF, a growth factor which stimulates sphingosine kinase
1, (ii) stimulation of endothelial cell growth and migration, (iii)
synergistic effects with various pro-angiogenic factors on the
neovascularization process, and (iv) inhibition of endothelial
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exoenzyme that is up-regulated in various cancers and generates
not only lysophosphatidic acid but also S1P [46], giving another
possibility to produce tumorigenic lipid mediators.
By stimulating inflammatory responses S1P could also help
to tumor development as inflammation is known to participate
to cancer promotion [47]. For example, TNF-treatment of tumor
cells activates sphingosine kinase 1, leading to an increased in-
tracellular S1P concentration, subsequent stimulation of COX2
expression and synthesis of PGE2 [48], which is considered as a
cancer-promoting eicosanoid.
Finally, through its binding to S1P receptors, S1P could
modulate differentiation, survival and migration of several im-
mune cell types, such as T and B lymphocytes (for reviews, see
[49,50]). Indeed, S1P reduces proliferation and regulates cytokine
secretion by T cells, increasing IL-10 and decreasing IFNγ pro-
duction [51]. These observations suggest that S1P could inhibit
Th1 response. The consequences of this putative inhibition on
Th1 anticancer immune responses are currently unknown.
In conclusion, tumorigenic effects of SLs largely exceed the
sole modulation of cell death. Hence, growing evidence indi-
cates that SLs exhibit mediator activity in immunity that could
affect anti-cancer immune responses. For instance, as mentioned
above, S1P and some gangliosides have immunosuppressive
effects on several immune cell-mediated cytotoxic mechanisms.
On the other hand, some SLs probably act as stimulators of
immune cells. The ambivalent role of SLs on the immune system
can be illustrated by the activating function of ceramides on
NKTcells. CD1d-restricted NKTcells have been identified as an
important component of the immune system, which has the
capacity both to augment beneficial host immunity, such as
tumor rejection, and to prevent harmful auto-immunity [52].
Activated NKT lymphocytes can mediate tumor cell lysis. In
addition these cells secrete large amounts of Th1 and Th2 cyto-
kines, including both pro-inflammatory and anti-inflammatory
cytokines. Consequently, they are considered as important regu-
lators of immune responses, with pleiotropic functions. Unlike
classical Tαβ lymphocytes that recognize peptides, NKT lym-
phocytes recognize glycolipid ligands such as α-galactosylcer-
amide [53]. Recently, isoglobotrihexosylceramide (iGb3), a
natural lysosomal SL, has been proposed as a natural ligand for
NKTand could be involved in the control ofNKTcell responses to
tumor cells [54]. In addition, mice immunized with GD3-positive
human melanoma cells, or with syngeneic antigen-presenting
cells loaded with GD3, develop a specific GD3-reactive NKT
population, suggesting that some gangliosides are possible ligands
for NKT lymphocytes [55].
2.2. Sphingolipids as tumor-suppressor molecules
Numerous observations have shown that certain SLs are able
to trigger caspase activation and apoptosis (recently reviewed in
[56]). Despite intensive research, however, the molecular me-
chanisms that intimately mediate the action of SLs in apoptosis
remain unclear. In addition, recent data indicate the possible
contribution of ceramide to alternative types of cell death. Thus,
ceramide and possibly some of its metabolites seem to becapable of activating programmed cell death not only through
caspase activation but also by caspase-independent mechanisms
[57–61]. Understanding how these programs are triggered and
regulated is of utmost importance in human cell biology and
pathology since it is now well established that their dysregula-
tion leads to many diseases including cancers.
2.2.1. Induction of apoptosis
Different studies underscore the putative function of ce-
ramide or its metabolites in stress-induced apoptosis in cancer
cells. First, diverse apoptotic stimuli led to the accumulation of
intracellular ceramide level in sensitive but not in resistant
cancer cells [62–65]. Distinct mechanisms including de novo
ceramide synthesis, sphingomyelin (SM) breakdown as well as
inhibition of ceramide conversion to complex SLs might con-
tribute to this phenomenon (see also Section 3). Second, incu-
bation of cancer cells in the presence of SL analogues triggered
caspase activation and apoptosis (see Section 4 and Table 2). The
mechanisms by which SLs induce caspase activation likely
involve mitochondrial events such as cytochrome c release since
overexpression of Bcl-2 or Bcl-xL counteracts SL cytotoxic
effects [6–8,66]. Third, modulation of ceramide metabolism
either by pharmacological or epigenetic strategies leading to
ceramide accumulation is accompanied by caspase activation
and apoptosis of cancer cells (see Tables 1 and 2). As a matter of
fact, reducing ceramide content can be associated with cancer
cell resistance to apoptosis [65].
Whereas different SL metabolites including ceramide [56],
sphingosine [67] and some gangliosides such as GD3 [68] have
been proposed to promote caspase activation, S1P [42,69] and
possibly GalCer [70] have an opposite effect.
2.2.2. Induction of lysosomal and autophagic cell death
While the existence of a ‘lysosomal pathway’ of cell death is
now accepted, the molecular mechanisms that underlie the
action of these organelles or components in the death cascades
are still unclear. In response to a variety of death stimuli, partial
lysosomal-membrane permeabilization (LMP) can occur, lead-
ing to the release of a class of proteases, cathepsins, that can
mediate apoptotic and non-apoptotic cell death [71,72]. SLs
have been associated with LMP due to the fact that sphingosine
could permeabilize lysosomal membranes and facilitate the
relocation of some lysosomal proteases to the cytosol [73].
Exogenous sphingosine, but not ceramide, can also permeabi-
lize in vitro isolated lysosome membranes [74]. In contrast,
exogenous SM has been reported to prevent lysosomal
disruption and the induction of apoptosis in photodynamic
therapy-treated murine hepatoma cells [75]. The role of SLs in
LMP is further supported by the finding that overexpression of a
dominant-negative form of FAN (Factor Associated with
Neutral sphingomyelinase activation), a protein known to
associate with TNF receptor-1 and to mediate the activation
of neutral sphingomyelinase (SMase), was accompanied by a
decrease in sphingosine generation and suppression of LMP in
rat hepatoma cells [76].
Even though LMP might be dependent on sphingosine,
ceramide generated by the endolysosomal acid SMase has also
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ceramide to the endolysosomal aspartate protease cathepsin D
results in the processing and the activation of the protease [77],
which, in turn, has been reported to be implicated in TNF- [78]
and UV light- [79] induced cell death. However, the role played
by cathepsin D in apoptosis seems to be independent of its
catalytic activity [80,81]. Interestingly, the interaction between a
cathepsin and another SL has also been demonstrated with the
observation that cathepsin B could reduce the levels of
antiapoptotic S1P during stress-induced tumor cell death [82].
Additional lysosomal proteins might be related to ceramide in
cell death signaling. Indeed, the product of the CLN3 gene
encoding battenin, a lysosomal transmembrane protein with
unknown function, which is mutated in some inherited neuro-
degenerative diseases, has been reported to prevent ceramide-
induced apoptosis [83]. Similar findings were obtained by using
CLN3 antisense constructs in human cancer cells [84].
Whereas lysosomal hydrolases are active components in cell
death induction [85], the implication of lysosomes in cell
dismantling has also been demonstrated through their role in
macroautophagy or autophagy. This process, which is defined as
a catabolic pathway for organelles and macromolecules, is also
classified as a programmed cell death mechanism [86]. Autophagy
is controlled by ATG genes whose products are essential in the
formation of the autophagosome and in the signaling pathways
related to autophagy [87]. SLs have been associated with
autophagy due to the fact that ceramide could mediate the tamox-
ifen dependent-autophagic cell death in human breast cancer
MCF-7 cells. Exogenous ceramide stimulates autophagy by re-
lieving the class I PI3K/Akt/PKB pathway and provoking the
accumulation of the tumor suppressor gene product Atg6/beclin 1
[88]. Similarly, a cell-permeable analogue of ceramide induces
autophagic cell death in glioma cells by increasing the expression
of the mitochondrial bound BH3-only BNIP3 protein [89]. In
contrast, S1P could stimulate autophagy by inhibiting mTOR
independently of the class I PI3K signaling and with a poor
stimulatory effect on beclin 1, suggesting that both SLs are able to
trigger autophagy, but with different outcomes on cell survival
[90].
Altogether, the afore-mentioned studies emphasize the
connection of SLs and lysosomes in the control of cell death.
However, future studies are obviously required to determine
precisely their contribution to LMP and the regulation of
autophagy.
2.2.3. Induction of mitotic catastrophe
Currently, a very limited number of observations suggest that
SLs could be involved in this yet poorly defined mode of cell
death which is characterized by cell cycle defects, aborted mi-
tosis and production of multinucleated cells. To our knowledge,
only the lysosphingolipid psychosine (β-galactosylsphingo-
sine), also known to trigger apoptotic cell death, has been
reported to induce inhibition of cytokinesis and the formation of
multinuclear cells [91]. This could account for the presence of
the so-called globoid cells in the nervous system of patients
affected with Krabbe disease, i.e., galactosylceramidase defi-
ciency, where psychosine accumulates. This effect of psychosinehas been described to be mediated by its binding to the orphan
receptor, T-cell death associated gene 8 (TDAG8) [92].
However, recent data indicate that this receptor is dispensable
for psychosine-induced inhibition of cytokinesis and glucocor-
ticoid-induced cell death of thymocytes [93].
2.2.4. Induction of other caspase-independent cell deaths
A growing body of evidence supports the involvement of
ceramide in caspase-independent cell death, that is, in cell death
processes that remain insensitive to the broad caspase inhibitor
zVAD-fmk. Exogenous ceramide analogues induced cancer cell
death, which was not, or partly, inhibitable by zVAD-fmk
[57,60,66,94–96]. In this context, ceramide stimulated p38
MAPK [60] and JNK activation [95]. Overexpression of Bcl-xL
inhibited ceramide analogue-induced cell death suggesting the
involvement of mitochondrial events [66]. In agreement with
this hypothesis, exogenous ceramides were shown to trigger
AIF (Apoptosis Inducing Factor) release from the mitochondria
[97]. The role of AIF in ceramide-induced caspase-independent
cell death remains to be established. In addition, ceramide has
been recently proposed as a mediator in TNF-induced caspase-
independent cell death in various cell lines [61]. In this last
study, it was reported that ceramide production involved RIP1
(Receptor-Interacting Protein), a serine/threonine kinase re-
quired for death receptors-induced caspase-independent cell
death [98]. In addition, TNF-induced ceramide production was
impaired in fibroblasts genetically deficient for acid SMase as
well as in L929 cells overexpressing acid ceramidase. Thus,
TNF-induced caspase-independent ceramide accumulation and
cell death likely involves RIP and acid SMase [61].
The type of caspase-independent cancer cell death induced
by ceramide has not been always fully characterized and
remains to be analysed in more details at the biochemical and
morphological levels. Some studies reported the possibility that
ceramide triggers essentially necrosis in certain cancer cell lines
[96,99,100].
3. Changes in sphingolipid metabolism associated with
resistance to anticancer treatments
A number of alterations in SL metabolism and individual SL
levels have been reported to accompany resistance of malignant
cells to anticancer regimens. These changes are described below.
3.1. Alterations in the sphingomyelin to ceramide balance
Two different types of enzymes, SM synthases and SMases
can regulate the SM to ceramide balance. SM synthase transfers
the phosphocholine moiety from phosphatidylcholine to cer-
amide to generate diacylglycerol and SM. Also, SM synthase
(SMS) may catalyze the reverse reaction [101]. Thus, it is
important to note that SMS can regulate in opposite directions
the levels of two bioactive molecules, the diacylglycerol and
ceramide [102]. Two different genes encoding SMS have been
cloned so far. The corresponding proteins, SMS1 and SMS2, are
mainly localized at the Golgi and at the plasma membrane,
respectively [103,104]. In SV40-transformed cells [105] as well
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is increased, this phenomenon being a putative mechanism to
up-regulate the level of the pro-proliferative diacylglycerol and
to decrease that of the anti-proliferative ceramide. Also, TNF
and FasL-induced cell death is accompanied by the decrease of
SMS activity, the inhibition of which might contribute to the
pro-apoptotic signaling notably by increasing ceramide cellular
content [106,107]. On the other hand, anti-Fas-induced
apoptosis is partly impaired in a murine leukemia cell line
having deficient SMS activity, whereas overexpression of SMS1
is accompanied by an increase of caspase activation and cell
death [108]. These conflicting observations might be explained
by (i) the structural function of SM in the constitution of cellular
membranes, (ii) the fact that SM can be a source of stress-induced
ceramide generation either by SMase activation or, possibly, by
stimulation of the reverse activity of SMS (a pathway that awaits
confirmation). Thus, a sustained inhibition of SMSmight alter the
physicochemical properties of membranes by SM depletion and
confer cell death resistance, whereas a transient inhibition (or
stimulation of the reverse activity) of SMS could be involved in
ceramide generation and apoptosis signaling.
SMase catabolizes SM leading to the generation of ceramide
and phosphocholine. Two types of SMases have been char-
acterized: acidic and neutral SMases. Acidic SMase, encoded
by the SMPD1 (sphingomyelin phosphodiesterase 1) gene
located on human chromosome 11, is mainly localized in the
endolysosomal compartment and can be secreted into the cel-
lular environment. Partial or total deficiency of acidic SMase
activity is responsible for Niemann–Pick disease, a lysosomal
storage disorder characterized by SM accumulation. Different
studies have highlighted the putative function of acidic SMase
in apoptosis [109,110] including in cancer cells [78]. One of the
putative mechanism by which acidic (secreted?) SMase is sup-
posed to promote cell death is by generating ceramide on the
outer leaflet of the plasma membrane enabling the oligomer-
ization of CD95 [111–113], CD40 [114] or CD20 [115]. The
formation of ceramide-enriched domains has also been reported
in cancer cells and in response to UV-light, cisplatin and other
inducers (for a recent review, see [116]). However, controversy
exists as to the ability of acidic SMase to be part of the cell death
signaling machinery in response to various agents including
agonists of CD95, CD40 and chemotherapeutic drugs [72,117–
119]. Acidic SMase has been proposed to be a component of the
TNF-RI receptosome [120].
Three neutral SMases, namely neutral SMase 1, 2 and 3 have
been cloned. Neutral SMase 1, encoded by SMPD2 gene located
on human chromosome 6, localizes at the endoplasmic reticulum
and the function of this enzyme in signaling and cell death is
controversial [121,122]. While neutral SMase 1 has been
claimed to mediate TCR-induced programmed cell death of a
T cell hybridoma [123], overexpression of this SMase had no
consequence on the viability of Jurkat cells and their sensitivity
to Fas-induced apoptosis [124]. Neutral SMase 2, encoded by
SMPD3 gene located on human chromosome 16, appears to
localize mostly at the Golgi but also at the plasma membrane,
and can be activated by TNF [125–127]. Whereas enforced
expression of neutral SMase 2 in MCF-7 breast cancer cellsinduced cell growth inhibition [126], neutral SMase 2 knock-
down was accompanied by an increase in cell proliferation
[128]. Previous reports showed the involvement of neutral
SMase in the pro-apoptotic signaling activated by TNF, chemo-
and radiotherapy [129,130]. Accordingly, we, and others, have
previously reported the role of FAN (Factor associated with
neutral sphingomyelinase activation) in TNF-induced caspase
activation and apoptosis in SV40-transformed fibroblasts [131]
and in hepatoma cells [76]. Similarly, FAN was shown to be
involved in CD40L- and hypoxia/reoxygenation-induced cell
death in SV40-transformed fibroblasts and cardiomyocytes,
respectively [118,132]. Very recently, a third neutral SMase,
encoded by SMPD4 gene located on human chromosome 2q21,
colocalizes with endoplasmic reticulum and Golgi markers, and
can be activated by TNF through the FAN adapter protein [133].
The role of this novel enzyme in cell death signaling remains to
be elucidated.
3.2. Alterations in the ceramide to sphingosine 1-phosphate
balance
Spiegel and co-workers have proposed that ceramide and S1P
exert opposite effects on cancer cell proliferation and death. In
this paradigm, while ceramide inhibits cell growth and promotes
apoptosis, S1P counteracts these effects. Thus, the ratio between
the two lipids would determine cell fate. Interestingly, recent
reports have highlighted alterations in the balance between
ceramide and S1P in cancer cells (see also articles by Spiegel et
al. [225] and Obeid et al. [224] in this issue). The levels of
ceramide and S1P can be directly regulated not only by
sphingosine kinases [134], but also by S1P phosphohydrolases
[135] and S1P lyase [136]. These enzymes regulate in opposite
directions the intracellular content of sphingosine that can be
converted to ceramide by ceramide synthase. Thus, over-
expression of sphingosine kinase 1 was accompanied by S1P
accumulation and concomitant ceramide decrease [134]. In
contrast, overexpression of S1P phosphohydrolase 1 in NIH3T3
led to S1P decrease and ceramide increase [135]. In addition,
accumulation of long-chain ceramide occurred in S1P lyase-
overexpressing HEK293 cells under serum starvation [136]. Of
note, sphingosine kinase 1 is overexpressed in certain tumor
tissues [137–139] whereas the human 10q21 chromosomal
region carrying the S1P lyase gene is deleted in a variety of
cancers [136]. The balance between ceramide and S1P is also
likely influenced by the rate of conversion of ceramide to
sphingosine, i.e., by the activity of ceramidases, which can affect
induction of cancer cell death [61,140].
3.3. Alterations in the ceramide to GlcCer/GalCer balance
In vitro selection of mammalian cells for resistance to a
specific chemotherapeutic drug frequently leads to cross-
resistance to a wide variety of cytotoxic agents, i.e., multidrug
resistance [MDR] (for review see [141]). In these cells, over-
expression of an integral membrane protein termed P-glycopro-
tein (P-gp), which is the gene product of MDR1, is responsible
for active efflux of a number of drugs thereby preventing them
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been described as presenting altered lipid compositions such as
elevated cholesterol, SM and various glycolipids (for review see
[142]). Among the latter, glucosylceramide (GlcCer) has been
proposed to play a significant role in MDR and P-gp regulation.
Indeed, in 1996, Cabot's group first demonstrated that drug-
resistant MCF-7/AdrR breast cancer cells accumulated GlcCer
in comparison to wild-type MCF-7 cells. This study was
followed by a series of studies which clearly demonstrated that
inhibition of GlcCer synthesis could sensitize MDR cells to
chemotherapeutic drugs whereas stimulation of GlcCer forma-
tion by glucosylceramide synthase (GCS) overexpression led to
increased doxorubicin resistance (for review see [143]; see also
Cabot and Gouaze-Andersson [226]).
Abnormally increased GlcCer synthesis may not be the sole
mechanism implicating glycolipids in the MDR phenotype. For
instance, Kok and coworkers have reported that multidrug
resistant ovarian cancer cells exhibit a defect in the coupling of
GlcCer and lactosylceramide biosynthesis [144], and that up-
regulation of lactosylceramide synthase is also associated with
resistance [145]. In addition, at least in some instances, GCS
expression does not influence cancer cell resistance to anti-
cancer drugs or regimens [146–148]. Whether the ability of
GCS to modulate the sensitivity to anticancer therapy is cell
type and/or drug-specific remains to be established.
Whatever the cause for a shift towards an increased ceramide
glucosylation, inhibition of the ceramide to GlcCer conversion
would be expected to prevent tumor development. As a matter
of fact, a number of observations have supported this tenet
whereby incubation of malignant cells with pharmacological
inhibitors of GCS resulted in chemo and/or radiosensitization,
and in delayed tumor formation (see Section 4). Of note, these
findings do not allow to distinguish between two potential
modes of action, that is, the suppression of glycosphingolipids
such as gangliosides which appear as crucial determinants in
tumor development and invasion (see Section 2.1), or the in-
creased intracellular content of the tumor-suppressor ceramide.
Our group has been investigating the role of ceramide and
ceramide metabolism notably in daunorubicin (DNR) and
aracytine (Ara-C)-induced apoptosis of leukemic cells. Using
clinically relevant DNR and Ara-C concentrations (1 μM and
40 μM, respectively), we have shown that these chemothera-
peutic drugs induced rapid (<6 h) interphasic apoptosis, and
stimulated an early (5–10 min) SM cycle (hydrolysis and
resynthesis) and subsequent ceramide generation in both U937
and HL-60 leukemic cells through the stimulation of a neutral
SMase [149,150]. It latter became apparent that ceramide me-
tabolites had a direct influence on cell response [56]. However,
the role of GCS in these non-MDR cells had largely been
overlooked. Surprisingly, we observed that while 1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP) derivatives
sensitized the MDR variants of U937 and HL-60 cells to both
DNR and Ara-C, these GCS inhibitors completely blocked drug-
induced apoptosis in the parental cell lines. Moreover, blocking
GCS did not lead to an increase in drug-induced ceramide
generation but to an increased GalCer content, which was not
observed in the MDR models [70]. To determine the potentialrole of GalCer in ‘protecting’ these leukemic cell lines, we
preincubated the cells with GalCer before drug treatment, and
observed significant decrease in apoptosis induction. Moreover,
treatment of Krabbe and Gaucher lymphoblasts, which are
inherently defective in GalCer and GlcCer lysosomal break-
down, respectively, with both drugs led to an intriguing result.
Indeed, compared to normal lymphoblasts, cells originating
from Krabbe patients were more resistant to both DNR and Ara-
C induced apoptosis, whereas Gaucher cells presented signif-
icantly greater sensitivity [70].
The contradictory observations concerning GCS inhibition
and cell response to cytotoxic effectors may lie in the complexity
of ceramide metabolism, which is likely cell and/or tissue-
specific. For example, in drug-sensitive Jurkat cells which
overexpress GCS, the ceramide generated by ligation of the
death receptor CD95, or etoposide, or ionizing radiation, was not
glycosylated [146]. In contrast, de novo synthesized ceramide as
well as an exogenously supplied cell-permeable ceramide anal-
ogue were efficiently glycosylated. The authors concluded that
GCS, located at the Golgi, is topologically segregated from
ceramide produced in the plasma membrane [146]. Therefore,
the ability of GCS overexpression to protect cells from possible
detrimental effects of ceramide accumulation is not a clear-cut
observation.
To make matters more complex, ceramide has long been
considered a pro-apoptotic mediator, and inhibition of GlcCer
synthesis leading to increased ceramide content has been
considered to be the mechanism by which PDMP sensitizes
MDR cells [151]. However, there is some controversy in the
matter (see below). There are also several studies showing that
apoptosis induction by ceramide requires its conversion to GD3
(for reviews see [68,152]). Since the first step in this conversion
is the glucosylation of ceramide, one would expect that cells
enriched in GlcCer would present higher sensitivity to apoptosis.
Indeed, Tepper and coworkers did notice a modest sensitization
of GCS-overexpressing Jurkat cells to CD95 ligation [146].
A close look at the literature suggests that blocking GlcCer
synthesis does not necessarily lead to increased apoptosis
[153,154]. Such discrepancies may be explained by the lack of
specificity of PDMP compounds towards GCS. Another
possible explanation would be differences in the basal levels
of GlcCer and GalCer. MDR cells indeed present elevated
GalCer as well as GlcCer levels [144,155]. It is therefore
tempting to propose that the relative balance (or imbalance) of
basal GalCer and GlcCer levels could represent a predisposition
for sensitivity or resistance to rapid interphasic SM-derived
ceramide-mediated apoptosis.
4. Manipulation of sphingolipidmetabolism and sphingolipid
analogues as anticancer tools
4.1. Genetic manipulation of sphingolipid metabolism
To clarify the functions of SLs in cancer cell death, a series of
studies using genetic or epigenetic approaches either to over-
express or knockdown enzymes of SL metabolism have been
undertaken. In addition, the sensitivity of cells derived from
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tabolism has been evaluated in response to different stress
stimuli. However, from the studies summarized in Table 1 that
illustrate the importance of SL metabolism in the modulation of
cancer cell death, it appears that some conflicting observations
have been published, which still make difficult to delineate a
clear-cut function for some enzymes in the regulation of cell
death. Besides possible bias due to the genetic alteration per se,
the impact of manipulation of SL metabolism is likely to be
dependent on cell type, stress stimulus and/or type of cell death.
4.2. Sphingolipid analogues
During the last decade, a number of compounds sharing
structural homology with simple SLs have been isolated from
natural sources or chemically synthesized. These SL analogues
have proved to be valuable tools for assessing the functions of
SLs in the regulation of cancer cell death.
4.2.1. Ceramide analogues
It has long been known that short-chain ceramides can (at least
in part) trigger cell death. More recently, a series of ceramide
analogues have been synthesized and shown to be cytotoxic for
leukemia or solid tumor cells both under cell culture conditions
and in animals (Table 2). Of interest, some of these synthetic
derivatives proved to be active also on drug-resistant cancer cells
(e.g., [66,156,157]) or hormone-insensitive tumor cells [158],
whereas they were less cytotoxic on non-cancer cells (e.g.,
[157,159]). Recently, systemic delivery of liposomal preparations
of C6-ceramide proved to exhibit growth inhibitory effects on
breast carcinoma tumors transplanted to mice [160].
4.2.2. Sphingosine analogues
Two derivatives of sphingosine, N,N-dimethylsphingosine
and dihydrosphingosine, are potent inducers of cell death in a
variety of malignant cell types (see [67] and references therein).
Some novel sphingosine analogues have recently been shown to
be even more cytotoxic for leukemia cells than the previous
derivatives [161].
FTY720 is another synthetic sphingosine derivative, with
analogy with myriocin. Several studies have highlighted the
FTY720 immunosuppressive properties that rely mainly on the
capacity of its phosphorylated form to desensitize S1P receptor
1 on lymphocyte cell surface [162]. This phenomenon is ac-
companied by the sequestration of lymphocytes into lymph
nodes. Recent publications have demonstrated the putative anti-
tumor effect of FTY720. In vitro, FTY720 induces cell death of
leukemia [163–166], glioma [167], breast cancer [168], prostate
cancer [169–171], bladder cancer [172], hepatocellular carci-
noma [173,174], and multiple myeloma cells [175]. FTY720
was shown to activate caspase and promote apoptosis in cancer
cells [164,169,172,173,175], and to trigger mitochondrial
events such as cytochrome c release [175]. FTY720-induced
cell death is likely independent of S1P receptor cross-linking
because micromolar concentrations are needed for triggering
cytotoxicity. Moreover, an analogue of FTY720 that cannot
bind S1P receptors is equally capable of inducing cell deathwithin the same concentration range [176]. In vivo, FTY720
inhibits tumor growth without notable side effects in mouse
models [168,171–174,177]. This phenomenon is likely a con-
sequence of FTY720-induced cancer cell death as well as an
inhibition of angiogenesis and metastasis [171,174], making
FTY720 and/or its derivatives promising candidate(s) for anti-
cancer therapy.
4.2.3. Glycosphingolipid analogues/inhibitors
As mentioned in Section 3.3, GlcCer appears to be an
important ceramide metabolite implicated in MDR. GlcCer was
initially proposed to stimulate cell proliferation [178]; also,
inhibitors of GCS could present antitumor effects [153,179].
These observations suggested that GCS plays a role in cell
survival. Indeed, cells overexpressing GCS were found to be
quite resistant towards anthracyclines [180], while transfection
of an antisense oligonucleotide directed against GCS sensitized
cells [181]. In MDR cells treated by chemotherapeutic agents,
ceramide is rapidly converted to GlcCer which makes GCS an
attractive target in MDR reversal [182]. A number of studies
using GCS inhibitors, which are structural analogues of GlcCer,
notably PDMP, 1-phenyl-2-palmitoylamino-3-morpholino-1-
propanol (PPMP), and 1-phenyl-2-hexadecanoylamino-3-pyr-
rolidino-1-propanol (P4) enhance chemotherapeutic drug effi-
cacy in MDR models [183–189]. Moreover, most agents which
reverse MDR (e.g., cyclosporine A, tamoxifen, verapamil) are
potent GCS inhibitors, and some others (e.g., PSC833) led to
increased ceramide levels through the activation of ceramide
synthase [190,191]. Attenuation of GlcCer synthesis (and,
consequently, of ganglioside biosynthesis) has also led to
significant reduction in tumor or metastasis development in
experimental settings using tumor xenografts or injection of
cancer cells in animals [19,187,192–194] (see Table 1).
As discussed earlier (Section 2.1), NKT lymphocytes are a T
cell subpopulation mediating cytotoxicity against various tumor
cells, either directly by using FasL, TNF or TRAIL, or in-
directly by enhancing antitumor immunity. NKT lymphocytes
are activated via antigen presentation by CD1d that is capable to
bind hydrophobic molecules such as glycolipids. Only recently,
iGb3 has been identified as a physiological CD1d ligand in mice
and humans. In addition, in the past few years, α-galactosylcer-
amide has been shown to be a potent stimulator of NKT cells.
This molecule is absent from mammals and was originally
purified from Agelas mauritianus. KRN7000 is a chemically
synthesized α-galactosylceramide and may be useful for the
treatment of cancer, directly by the way of NKT activation and
indirectly by stimulating dendritic cell functions and IFNγ/IL-
12 production [195]. Several phase I trials in patients with solid
tumors have been recently performed, demonstrating good drug
tolerance [196].
5. Concluding remarks
In conclusion, we now know that SLs play an essential part in
the regulation of cancer cell death and tumor development, and it
will most certainly be of great importance to delineate their exact
role in cell signaling (survival, death, proliferation). This review
2114 B. Ségui et al. / Biochimica et Biophysica Acta 1758 (2006) 2104–2120incites for a reinterpretation of the actions of SLs in the light of
recent advances in the basic sciences which should allow, for
example, for cellular pharmacology of anti-neoplastic agents to
continue gathering momentum in the perspective of overcoming
drug resistance by defining new strategies capable of sensitizing
resistant tumor cells and/or protecting normal physiological
cells.
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